<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We previously reported the cloning, and characterization of a receptor tyrosine kinase, axl, from two patients with <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Herein, we describe the expression pattern of axl in <z:mpath ids='MPATH_458'>normal</z:mpath> and malignant hematopoietic tissue axl message is detected in <z:mpath ids='MPATH_458'>normal</z:mpath> human bone marrow but not significantly in <z:mpath ids='MPATH_458'>normal</z:mpath> blood leukocytes </plain></SENT>
<SENT sid="2" pm="."><plain>Cell separation experiments showed that axl is expressed in hematopoietic CD34+ progenitor and marrow stromal cells, at low levels in peripheral monocytes, but not in lymphocytes or granulocytes </plain></SENT>
<SENT sid="3" pm="."><plain>Consistent with the <z:mpath ids='MPATH_458'>normal</z:mpath> pattern of axl expression, axl <z:chebi fb="40" ids="33697">RNA</z:chebi> was found predominantly in diseases of the myeloid lineage: 39 of 66 (59%) patients with <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase, <z:mp ids='MP_0005481'>CML</z:mp> in myeloid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e>, and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>) showed significant axl transcription, as compared with 1 of 45 (2%) <z:hpo ids='HP_0005526'>lymphoid leukemias</z:hpo> (<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and <z:mp ids='MP_0005481'>CML</z:mp> in lymphoid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment of K562 cells with the <z:chebi fb="0" ids="37532">phorbol ester</z:chebi>, 12-O-tetradecanoylphorbol-13-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (<z:chebi fb="6" ids="15702,53394">TPA</z:chebi>), administration of interferon alpha (IFN alpha) to <z:mpath ids='MPATH_458'>normal</z:mpath> monocytes, and treatment of U937 cells with <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> and IFN tau significantly induced axl expression, supporting a role for this kinase in the intracellular signaling of myeloid cells through a variety of biochemical pathways </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest that the axl kinase may be operative in <z:mpath ids='MPATH_458'>normal</z:mpath> and malignant myeloid biology </plain></SENT>
</text></document>